HOYA's New Lens Halts Myopia, Reshaping a Multi-Billion Dollar Market

MISSISSAUGA, ON – July 30, 2026

Japanese med-tech giant HOYA has fired its most powerful shot yet in the escalating war against childhood myopia. The Canadian launch of its MiYOSMART® iQ spectacle lens is more than a product release; it's a strategic move backed by startling clinical data that could fundamentally alter the economics and standard of care for a condition projected to affect half the world's population by 2050. With results showing the lens halts myopia progression on average in nine out of ten children, HOYA is positioning itself to dominate a market born from a global public health crisis.

A Generational Leap in Vision Technology

At the heart of the launch are clinical results that have set a new benchmark in non-invasive myopia control. In a randomized controlled trial presented at the prestigious ARVO 2026 Annual Meeting, children aged 4-12 wearing the MiYOSMART iQ lenses showed no average progression of their near-sightedness over a 12-month period. For older children aged 7-12, the results were even more pronounced, demonstrating what HOYA reports as over 100% efficacy in controlling refractive error progression.

The lens builds on HOYA’s existing D.I.M.S. (Defocus Incorporated Multiple Segments) Technology, which is supported by over 100 peer-reviewed papers. The new 'iQ' version introduces a 'Triple Enhanced Design' (TED) that refines the science. This involves positioning hundreds of small lens segments closer to the lens's center, increasing their power, and extending the treatment zone. The design creates a specific type of peripheral blur, or 'myopic defocus,' that signals the eye to slow its axial elongation—the primary driver of myopia progression in children.

"This milestone is truly a generational leap in myopia control," said John Goltermann Lassen, CEO of HOYA Vision Care, in a statement. The company's confidence is bolstered by a key breakthrough: demonstrating efficacy in children as young as four. For this critical 4-6 age group, where myopia can progress most rapidly, the iQ lens showed a 65% control efficacy. "These findings demonstrate—for the first time with myopia control spectacle lenses—efficacy in children from 4 years of age with early-onset myopia," noted Dr. Natalia Vlasak, HOYA’s Global Head of Medical and Scientific Affairs.

The Economics of a Global Health Crisis

The strategic importance of MiYOSMART iQ cannot be understood without grasping the scale of the problem it aims to solve. Myopia is no longer a simple inconvenience corrected by glasses; it is a pandemic in slow motion. In Canada, prevalence has surged, with one study showing an increase from 6% in children aged 6-8 to nearly 30% by ages 11-13. Some estimates place the current rate for all Canadian children at 25%, a sharp rise from 17.5% in 2018, with the indoor, screen-focused lifestyles of the COVID-19 era acting as a potent accelerant.

This trend carries a significant future cost. High myopia dramatically increases the risk of sight-threatening diseases later in life, including glaucoma, retinal detachment, and myopic macular degeneration. By intervening early to slow or halt progression, the long-term public health burden can be substantially reduced. This intersection of public health need and market opportunity is where companies like HOYA are placing their bets. The potential return on investment is enormous, not just in lens sales but in establishing a long-term relationship with patients and eye care professionals.

A Calculated Play in a Crowded Market

HOYA's market entry in Canada is a carefully calculated two-pronged attack. The new, premium MiYOSMART iQ is being offered alongside the original MiYOSMART lens, which has already been sold to over 15 million parents worldwide since 2018. This creates a tiered portfolio: the original DIMS lens as a proven, accessible option, and the iQ lens as the high-efficacy solution for early-onset or rapidly progressing cases. "I've seen many innovations over the years, but MiYOSMART iQ is truly exceptional," stated Ryan McAdam, Managing Director of HOYA Vision Care, Canada.

However, this powerful new tool comes at a cost, and accessibility remains a critical variable. Myopia control is not a one-time purchase but a multi-year commitment, and it is not covered by provincial health plans like OHIP. While specific pricing for iQ is set by individual practitioners, the existing market provides a guide. A year of treatment with myopia control spectacle lenses can run from $850 to $1,700, competing with other modalities like atropine eye drops ($1,000-$1,800 annually) and Ortho-K lenses (upwards of $2,200 for the first year). For many families, the decision will involve a complex calculation of cost versus benefit, a factor that will ultimately shape the technology's real-world impact.

To manage its brand and ensure proper application, HOYA requires eye care professionals to complete a certification program before they can dispense the lenses, a strategy that ensures quality control while reinforcing the product's premium, medical-grade positioning. This combination of groundbreaking science, a tiered product strategy, and a controlled distribution channel demonstrates a sophisticated understanding of the mechanics of power and profit in the modern med-tech landscape.